$NTHI

NeOnc Technologies (NTHI) said the FDA provided written feedback on NEO212, a potential treatment for malignant brain tumors and other CNS cancers. FDA said the CMC approach is reasonable but requested additional comparative assessments if manufacturing or physical characteristics change. The agency allowed the drug-product plan to proceed alongside late-stage trials, with stability and a capsule-to-tablet bioavailability study. NTHI shares were $4.03, up 9.51% on Nasdaq.

NeOnc Technologies Holdings said the U.S. FDA provided written feedback on the CMC program for its NEO212 temozolomide-perillyl alcohol conjugate ahead of an End-of-Phase 1 meeting it later canceled. The FDA said the CMC approach is reasonable, outlined stability and capsule-to-tablet transition requirements, including an in vivo relative bioavailability study and GMP batch. NeOnc will update its plan.

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001979414 0001979414 2026-06-27 2026-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of repor

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 neonctechnologies_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 10, 2026, is entered into by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the “Company”

Alliance Global initiated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI) on May 19 with a Buy rating and a $13 price target, citing intranasally delivered small-molecule therapies for glioma and glioblastoma. Maxim initiated coverage a day earlier with a Buy rating and a $20 target. The article says NeOnc’s NEO platform aims to cross the blood-brain barrier.

The article lists eight “up and coming” penny stocks, selected via screeners for IPOs in the past five years and recent developments. It highlights NeOnc Technologies (NTHI) at $4.64, with Alliance Global and Maxim initiating Buy ratings and $13/$20 targets, and AirJoule (AIRJ) at $4.49, after a Q1 update and Seaport Research’s $7 Buy target.

Shares of Neonc Technologies (NASDAQ:NTHI) fell 0.1% during mid-day trading on Wednesday, March 14, 2026, amid lower than average trading volume. The biotech company, which is developing treatments for central nervous system diseases, has received mixed analyst ratings, with one firm issuing a "sell" and another a "hold." Investors are closely monitoring the stock's performance as the company advances its lead drug candidates, NEO100 and NEO212, through clinical trials.

NeOnc Technologies Holdings, Inc. has announced the results of its Phase 1 clinical trial for NEO212, an oral bio-conjugated therapy for recurrent glioblastoma and brain metastases. The company successfully established 610 mg as the recommended Phase 2 dose, observing early signs of clinical efficacy. This milestone validates NeOnc's CNS oncology platform and prepares the company for Phase 2 expansion studies.

NeOnc Technologies (NTHI) has set the Recommended Phase 2 Dose (RP2D) for its oral drug NEO212 at 610 mg, following a Phase 1 dose-escalation study that reached the Maximum Tolerated Dose (MTD) at 810 mg. The company observed early signs of anti-tumor activity and durable disease control, alongside a favorable safety profile. NeOnc plans to advance to Phase 2 expansion studies, aiming for potential accelerated approval pathways.

CALABASAS, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- NeOnc Technologies Holdings, Inc. ( NTHI ) ( "NeOnc" or the "Company" ) , a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system ( CNS ) ...